Manufacturing Process and MoA of IGV-001



This figure was created with BioRender.com and then further modified.

1. Tumor cells treated with IMV-001 antisense are placed in biodiffusion chambers (BDCs) and irradiated
2. Tumor cells undergo stress leading to immunogenic cell death (ICD)
3. ICD results in production of high mobility group box 1 (HMGB1) and damage-associated molecular patterns (DAMPs) which are released from stressed/dying cells inside the BDCs and from the surrounding damaged tissue at the abdominal implantation site
4. Simultaneously, ICD results in a tumor antigen payload (<0.1 µm in size) being released from the BDCs
5. Dendritic cells (DCs) are recruited by DAMPs adjuvanticity and mature upon tumor antigen uptake
6. DC-primed T cells undergo clonal expansion, and tumor-antigen specific T cells kill tumor cells

Cultrara C, et al. *J Immunother Cancer*. 2023;11(8):e006880.